| Bioactivity | RLA-4842 is an iron activator containing anti-androgen. RLA-4842 has anti-proliferative activity on metastatic castration-resistant prostate cancer (mCRPC) cell line[1]. |
| Invitro | RLA-4842 (compound 9) (0-25 µM；10 min) 以浓度依赖性方式抑制 LNCaP-AR 细胞增值[1]。RLA-4842 (5 µM；0-6 d) 对 VCaP、PC3、LNCaP 和 C4-2B 细胞增值有抑制作用[1]。RLA-4842 (5 µM；24 h) 下调了 LNCaP 细胞中 KLK-2 和 KLK-3 的表达水平[1]。 Cell Viability Assay[1] Cell Line: |
| Name | RLA-4842 |
| Formula | C42H46F3N5O8S |
| Molar Mass | 837.90 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Gonciarz RL, et al. Elevated labile iron in castration-resistant prostate cancer is targetable with ferrous iron-activatable antiandrogen therapy. Eur J Med Chem. 2023 Jan 14;249:115110. |